Jedd D. Wolchok

Top papers

• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

  F. Stephen Hodi, Steven O’Day, David F. McDermott, et al.·2010·New England Journal of Medicine
  ↗ 15,080OA
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

  James Larkin, Vanna Chiarion‐Sileni, René González, et al.·2015·New England Journal of Medicine
  ↗ 8,092OA
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, et al.·2015·Science
  ↗ 7,896
• Cancer immunotherapy using checkpoint blockade

  Antoni Ribas, Jedd D. Wolchok·2018·Science
  ↗ 6,578OA
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, et al.·2017·New England Journal of Medicine
  ↗ 5,360OA
• Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

  Caroline Robert, L. Thomas, Igor Bondarenko, et al.·2011·New England Journal of Medicine
  ↗ 4,456OA
• Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

  Alexandra Snyder, Vladimir Makarov, Taha Merghoub, et al.·2014·New England Journal of Medicine
  ↗ 4,366OA
• Tumor mutational load predicts survival after immunotherapy across multiple cancer types

  Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, et al.·2019·Nature Genetics
  ↗ 4,323OA
• Nivolumab plus Ipilimumab in Advanced Melanoma

  Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, et al.·2013·New England Journal of Medicine
  ↗ 4,211OA
• Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

  Héctor Peinado, Maša Alečković, Simon Lavotshkin, et al.·2012·Nature Medicine
  ↗ 3,689OA
• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  James Larkin, Vanna Chiarion‐Sileni, René González, et al.·2019·New England Journal of Medicine
  ↗ 3,665OA
• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

  Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, et al.·2018·Journal of Clinical Oncology
  ↗ 3,646OA